10-QFiled 4 Nov 2026Biotech
uniQure N.V.QURE
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
The nightly ledger
Every 8-K, 10-Q and 10-K that AIR's companies filed on SEC EDGAR, and what each one changed in AIR's read. Material filings first, newest first — never ordered by price. For 8-K filing alerts, follow a company and turn on filing emails.
By event type: Acquisitions · Major contracts
Seven-day window, 2 weeks back · Material filings: 1629 · All filings: 1839
Wednesday 4 Nov473 filings read · 428 material
10-QFiled 4 Nov 2026Biotech
uniQure N.V.QURE
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026Biotech
Harmony Biosciences Holdings, Inc.HRMY
8-K · Item 2.02 — Results of operations
Q3 2026: WAKIX net revenue $269M (12% YoY growth) with 400 net patient adds. Company reiterates full-year guidance of $1.0–$1.04B. BP-205 MAD study shows favorable safety/tolerability; Phase 1b data expected Q1 2027. Pitolisant GR NDA under FDA review (PDUFA April 2027). Leadership transition announced.
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026Biotech
Harmony Biosciences Holdings, Inc.HRMY
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 25 Sep 2026
The gap narrowed — attention is catching up.
The price trend strengthened.
8-KFiled 4 Nov 2026All industries
PureCycle Technologies, Inc.PCT
8-K · Items 2.02, 5.02 — Results of operations
Q3 2026 revenue $2.3M (down from Q2 due to operational issues and NJ delays), but production recovered to 5.2M lbs (+14% QoQ). P&G products on shelves, railcar shipments begun, cosmetics shipments expected Q4. Fernando Musa appointed Executive Chairman to support commercial ramp. $393M total liquidity.
Progress is running ahead of attention.
10-QFiled 4 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 4 Nov 2026All industries
Grand Canyon Education, Inc.LOPE
8-K · Item 2.02 — Results of operations
GCE reported Q3 2026 results with 185.6% operating income growth to $51.5M, driven by 5.2% enrollment increase to 145,270 students. Net income rose 164.3% to $43.0M. Board approved $355M share repurchase increase. Full-year guidance provided.
No notable change in AIR's read.
10-QFiled 4 Nov 2026Biotech
Nrc HealthNRC
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The price trend weakened.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Enact reported Q3 2026 net income of $159M ($1.15/share) and adjusted operating income of $164M ($1.19/share). Primary IIF grew 1% YoY to $275B. Loss ratio increased to 20% from 14% sequentially. Capital return guidance raised to ~$600M for 2026.
No notable change in AIR's read.
8-KFiled 4 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
Joby raised FY2026 revenue guidance 15% to $135–140M. Completed key FAA certification tests, began eIPP flights in Texas/Florida, expanded Air Force contracts to ~$37M, and announced acquisition of EBITDA-positive Resonant Sciences ($100M+ revenue). Blade achieved record 44K+ passengers Q3.
No notable change in AIR's read.
10-QFiled 4 Nov 2026Software / SaaS
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 4 Nov 2026All industries
Grand Canyon Education, Inc.LOPE
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 4 Nov 2026All industries
Root, Inc.ROOT
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
Q3 2026 revenue grew 18.8% YoY to $212.2M; net income nearly doubled (+97.2%) to $6.1M. Company reaffirms full-year guidance, expands product line (65-ton rotator), advances $100M capacity expansion, and reports $200M+ military commitments with production starting 2027.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026All industries
Root, Inc.ROOT
8-K · Item 2.02 — Results of operations
Root reported Q3 2026 revenue of $381M, net income of $14M, and adjusted EBITDA of $34M with 97.2% net combined ratio. Partnership channel grew 19% YoY. Renewed Carvana relationship through 2028, launched Hyundai pilot, expanded to Wyoming, and deployed new pricing model.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 4 Nov 2026Biotech
Arcutis Biotherapeutics, Inc.ARQT
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026Biotech
Arcutis Biotherapeutics, Inc.ARQT
8-K · Item 2.02 — Results of operations
Arcutis reported Q3 2026 net product revenue of $143.9M (+45% YoY, +11% QoQ), raised full-year 2026 guidance to $535–$545M, and advanced pipeline including Phase 3 atopic dermatitis trial and vitiligo Phase 2 results expected Q4 2026.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026Industrials
XPEL, Inc.XPEL
8-K · Item 2.02 — Results of operations
XPEL reported Q3 2026 revenue of $137.8M (+9.9% YoY) with gross margin expansion to 44.6% (+280 bps). Net income grew 26.3% to $16.3M ($0.59 EPS). Nine-month revenue up 12.5% to $398.2M with 18.3% net income growth.
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026Biotech
Vaxcyte, Inc.PCVX
8-K · Item 2.02 — Results of operations
Vaxcyte announced positive topline data from OPUS-1 Phase 3 trial of VAX-31, meeting all prespecified primary immunogenicity endpoints. Company raised $1.1B in net proceeds and expects OPUS-2/OPUS-3 results in H1 2027, supporting planned BLA submission in H1 2028.
The gap narrowed — attention is catching up.
The price trend strengthened.
8-KFiled 4 Nov 2026Biotech
Adaptive Biotechnologies CorpADPT
8-K · Item 2.02 — Results of operations
Adaptive Biotechnologies achieved Q3 2026 profitability ahead of expectations with $14.3M adjusted EBITDA and $7.7M free cash flow. MRD revenue grew 44% (excluding milestones). Company raised full-year MRD revenue guidance to $276–$286M (30–35% growth). clonoSEQ test volume increased 46% YoY.
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 results show strong year-over-year growth: revenue +32.0% to $302.3M, net income +58.5% to $9.6M, adjusted EBITDA +42.4% to $24.7M. Home health admissions +39.4%, hospice census +34.6%. Company on track with full-year guidance.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026All industries
Acadia Healthcare Company, Inc.ACHC
8-K · Item 2.02 — Results of operations
Acadia Healthcare reported Q3 2026 revenue of $895.3M (+5.1% YoY) with Adjusted EBITDA of $176.4M (+2% YoY). Company raised full-year 2026 guidance significantly: Adjusted EBITDA now $615–625M (vs. prior $590–615M) and Adjusted EPS $1.70–1.80 (vs. prior $1.45–1.60).
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 4 Nov 2026Industrials
Insulet CorpPODD
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $842M grew 19.2% (19.6% constant currency), beating guidance high-end. Operating margin expanded 590 bps. Company authorized $1B share repurchase program with $400M allocated to Q4 2026. Full-year guidance raised for Omnipod segments.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Permian Resources reported strong Q3 2026 results with 22% quarter-over-quarter production growth to 457.5 MBoe/d, record-low controllable cash costs of $7.05/Boe, $846M adjusted free cash flow, and completed $1.15B in acquisitions including Ridge Runner. Raised full-year oil production guidance to 202.5 MBbls/d.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026Industrials
Bruker CorpBRKR
8-K · Item 2.02 — Results of operations
The shares became dearer on AIR's value read.
The price trend strengthened.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026Software / SaaS
Taboola.com Ltd.TBLA
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
The price trend weakened.
8-KFiled 4 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
Envista reported Q3 2026 results with core sales growth of 2.7%, adjusted diluted EPS of $0.40 (+25% YoY), and adjusted EBITDA margin expansion of 80 bps. Company raised full-year 2026 guidance for core sales growth, adjusted EBITDA growth, and adjusted diluted EPS.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 4 Nov 2026All industries
Interparfums IncIPAR
8-K · Items 2.02, 8.01 — Results of operations
Q3 2026 net sales flat at $430M; nine-month sales +1% to $1.1B. Gross margin expanded 160–360 bps. Diluted EPS +2–4% YoY. Company raised full-year 2026 sales guidance to $1.49B and maintained EPS outlook of $4.85, citing strong brand momentum and portfolio resilience.
More of the market is starting to notice.
The shares became dearer on AIR's value read.
The price trend strengthened.
10-QFiled 4 Nov 2026All industries
Blue Owl Technology Finance Corp.OTF
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 4 Nov 2026All industries
Victory Capital Holdings, Inc.VCTR
8-K · Item 2.02 — Results of operations
Victory Capital reported record Q3 2026 results: $355.5B AUM, $30.5B gross sales, $11.7B net inflows (14% annualized organic growth), 53.5% adjusted EBITDA margin, and announced definitive First Eagle Investments acquisition.
No notable change in AIR's read.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
e.l.f. Beauty reported Q2 FY2027 net sales growth of 51% YoY to $520.8M, marking 31 consecutive quarters of growth. Company raised full-year FY2027 net sales guidance from 18-20% to 22-24% and increased adjusted EBITDA and EPS guidance.
Progress is running ahead of attention.
The price trend strengthened.
Tuesday 3 Nov307 filings read · 258 material
8-KFiled 3 Nov 2026Semiconductors
8-K · Item 2.02 — Results of operations
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 3 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 3 Nov 2026Semiconductors
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $287.5M grew 15% YoY, exceeding guidance midpoint. Net income surged 171% to $20.3M; diluted EPS of $0.47 vs. $0.18 prior year. Gross margin expanded to 40.7%. Advanced Solutions grew 33% YoY.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
10-QFiled 3 Nov 2026All industries
Sixth Street Specialty Lending, Inc.TSLX
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 3 Nov 2026Industrials
Revvity, Inc.RVTY
8-K · Items 2.02, 8.01 — Results of operations
Revvity reported Q3 2026 revenue of $729M (pro forma $710M, +7% organic growth) and adjusted EPS of $1.38, beating expectations. Company raised full-year 2026 guidance to $2.86B revenue and $5.40–$5.45 adjusted EPS. Both segments showed strong performance.
Progress is running ahead of attention.
10-QFiled 3 Nov 2026All industries
Independence Realty Trust, Inc.IRT
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 3 Nov 2026All industries
Hni CorpHNI
8-K · Item 2.02 — Results of operations
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
10-QFiled 3 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 3 Nov 2026All industries
Marzetti CoMZTI
Quarterly report (10-Q), period ending 30 Sep 2026
The gap narrowed — attention is catching up.
The price trend strengthened.
10-QFiled 3 Nov 2026All industries
Corebridge Financial, Inc.CRBG
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 3 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The gap closed as the filings read less positively.
The price trend weakened.
10-QFiled 3 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 3 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
The price trend strengthened.
10-QFiled 3 Nov 2026All industries
Quarterly report (10-Q), period ending 3 Oct 2026
The gap closed as the filings read less positively.
The price trend weakened.
10-QFiled 3 Nov 2026All industries
UDR, Inc.UDR
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 3 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 3 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 3 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 revenue grew 3.0% to $1.28B with net income up 31.4% to $22.2M. Gross margin expanded to 25.5% from 24.8% YoY. EPS increased to $0.90 from $0.69. Headwinds included pharmacy pricing pressure ($14.56M) and produce weakness from Cyclospora outbreak.
More of the market is starting to notice.
The price trend strengthened.
10-QFiled 3 Nov 2026Banks
South Plains Financial, Inc.SPFI
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
The price trend weakened.
10-QFiled 3 Nov 2026All industries
Valaris LtdVAL
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 3 Nov 2026Software / SaaS
Jack Henry & Associates IncJKHY
8-K · Item 2.02 — Results of operations
JKHY reported Q1 FY2027 results exceeding guidance with GAAP revenue +8.8%, operating income +12.5%, and EPS +15.6% YoY. Full-year guidance raised; strong momentum in cloud, card, and digital segments.
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 3 Nov 2026Banks
Atlantic Union Bankshares CorpAUB
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 3 Nov 2026All industries
Omega Healthcare Investors IncOHI
8-K · Item 2.02 — Results of operations
Q3 2026: Net income $87M ($0.27/share), AFFO $262M ($0.82/share, +3.8% YoY), FAD $250M ($0.78/share, +4% YoY). Completed $1.5B investments YTD. Raised full-year AFFO guidance midpoint by $0.05 to $3.29. Operator coverage improved; leverage at historic lows.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 3 Nov 2026All industries
8-K · Items 2.02, 5.02 — Results of operations
Yum China reported Q3 2026 results with 8% revenue growth, 13% operating profit growth, and 20% diluted EPS growth. Achieved record net new store openings (692 quarterly), 15th consecutive quarter of same-store transaction growth, and 10th consecutive quarter of OP margin expansion.
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 3 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Beam reported Q3 2026 results with multiple clinical advances: BEAM-302 showed durable AAT increases with potential accelerated approval path; risto-cel BLA submission expected year-end 2026; BEAM-301 demonstrated clinical proof-of-concept in GSDIa; BEAM-304 Phase 1/2 initiation planned early 2027. Cash runway extended to mid-2029.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 3 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 3 Nov 2026All industries
PennyMac Mortgage Investment TrustPMT
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The price trend strengthened.
8-KFiled 3 Nov 2026All industries
Henry Schein IncHSIC
8-K · Item 2.02 — Results of operations
Henry Schein reported Q3 2026 GAAP EPS of $1.06 (up 26.2%) and non-GAAP EPS of $1.56 (up 13.0%). Company raised FY2026 non-GAAP EPS guidance to $5.50–$5.56 and Adjusted EBITDA growth to high-single-digits, driven by strong U.S. dental merchandise sales growth of 8.6% and market share gains.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
10-QFiled 3 Nov 2026All industries
Henry Schein IncHSIC
Quarterly report (10-Q), period ending 26 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
10-QFiled 3 Nov 2026Biotech
Biomarin Pharmaceutical IncBMRN
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
The gap narrowed as the filings read less positively.
The price trend weakened.
8-KFiled 3 Nov 2026Industrials
BALL CorpBALL
8-K · Item 2.02 — Results of operations
Ball Corporation reported Q3 2026 comparable diluted EPS of $1.10 (up 6.8% YoY), comparable operating earnings of $451M (up 2.5%), and global aluminum packaging shipments up 4.7%. Company raised 2026 EPS guidance to 10%+ growth and announced new manufacturing facilities in Germany and India.
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 3 Nov 2026All industries
EchoStar CORPECHO
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 3 Nov 2026Industrials
BALL CorpBALL
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 3 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 3 Nov 2026Industrials
Mayville Engineering Company, Inc.MEC
8-K · Item 2.02 — Results of operations
Q3 2026 net sales grew 18.1% YoY to $170.4M, driven by 64.9% growth in Datacenter & Critical Power. Company secured $45M in new awards, pipeline exceeds $200M, and closed Thomson, Georgia acquisition expected to add ~$50M annual capacity by 2028.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 3 Nov 2026All industries
H2O AmericaHTO
8-K · Items 1.01, 2.03, 8.01 — Material agreement
H2O America completed issuance of 7.475 million corporate units at $50 stated amount via underwriting agreement with Wells Fargo and J.P. Morgan. Units comprise stock purchase contracts and senior notes with 7.75% annual distributions.
The gap narrowed — attention is catching up.
The price trend strengthened.
8-KFiled 3 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Assurant delivered Q3 2026 double-digit earnings growth (12% ex-catastrophes), raised full-year Adjusted EBITDA growth outlook to ~10% and Adjusted EPS to low double digits, increased share repurchase authorization to $350M, and achieved 10th consecutive year of profitable growth.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
10-QFiled 3 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
The filings read more positively.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 3 Nov 2026Biotech
Aquestive Therapeutics, Inc.AQST
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 3 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 3 Nov 2026Software / SaaS
8-K · Item 2.02 — Results of operations
Q3 2026 revenues grew 17% YoY to $189.5M; SaaS revenues surged 47% to $185.1M. SaaS ARR reached $774.6M (+42% YoY). Non-GAAP operating income improved to $7.6M vs. $0.2M prior year. Pending Proofpoint acquisition by Thoma Bravo creates uncertainty; no forward guidance provided.
No notable change in AIR's read.
8-KFiled 3 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 earnings: NII $0.33/share (flat sequentially), distribution $0.31/share declared. NAV declined to $17.83 from $18.00. Portfolio performing well with 98.8% on-accrual; two non-accruals at 1.2% fair value. $575M originations, $850M+ capital available.
No notable change in AIR's read.
10-QFiled 3 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
The price trend weakened.
10-QFiled 3 Nov 2026All industries
Bowhead Specialty Holdings Inc.BOW
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 3 Nov 2026All industries
Healthpeak Properties, Inc.DOC
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 3 Nov 2026Semiconductors
Navitas Semiconductor CorpNVTS
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
8-KFiled 3 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
IDEAYA completed NDA submission for darovasertib in metastatic uveal melanoma, presented supportive ESMO data across multiple indications, initiated Phase 3 trials for IDE849, and maintains $1.15B cash runway into 2030. Offset by OptimUM-010 trial closure and increased operating losses.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 3 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Cinemark reported Q3 2026 results with net income up 146% YoY to $124M, revenue of $1.1B (highest Q3 ever), and Adjusted EBITDA of $268M with 460 bps margin expansion. Record premium format and concession performance.
Progress is running ahead of attention.
8-KFiled 3 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 revenue declined 8.4% YoY to $182.2M; gross margin collapsed to 23.1% from 37.7%; net loss of $6.5M vs. prior-year profit of $16.4M. FY2026 guidance slashed: revenue cut to ~$730M (from $775–800M), EBITDA revised to ~$(15)M loss (from $0–10M gain). Long-term 2030 targets withdrawn.
More of the market is starting to notice.
The price trend strengthened.
8-KFiled 3 Nov 2026Biotech
Alkermes plc.ALKS
8-K · Item 2.02 — Results of operations
Alkermes reported Q3 2026 revenues of $480.1M (+22% YoY) with GAAP net income of $16.3M and Adjusted EBITDA of $120.1M. Company reiterates 2026 financial guidance. New product LUMRYZ contributed $89.9M in quarterly revenue.
No notable change in AIR's read.
8-KFiled 3 Nov 2026All industries
8-K · Items 1.01, 3.02 — Material agreement
CVR Energy agreed to acquire two refineries (St. Paul Park and Mandan) plus logistics assets from Marathon Petroleum for $4.2B base price, with $800M equity investment from Trafigura and up to $500M from Icahn Enterprises.
The filings read more positively.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 3 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 3 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 3 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 results exceeded expectations with 37.6% YoY order growth, 10.9% sales growth, 120% net income growth, and 39% adjusted EBITDA growth. Company raised full-year adjusted EBITDA and EPS guidance, citing strong crane demand and four consecutive quarters of backlog expansion.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 3 Nov 2026All industries
Sixth Street Specialty Lending, Inc.TSLX
8-K · Item 2.02 — Results of operations
Q3 2026 earnings: NII per share $0.44, net income $0.36. NAV declined to $16.19 from $16.24. Base dividend $0.42 declared; supplemental $0.01. Portfolio quality stable with non-accrual at 1.8% of cost.
No notable change in AIR's read.
10-QFiled 3 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 3 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Mercury General reported Q3 2026 net loss of $13.7M vs. $280.4M profit in Q3 2025, driven by $262M in net realized investment losses from rising interest rates. YTD results remain positive at $440.2M net income, up 30% YoY.
Market attention has faded.
The gap closed as the filings read less positively.
The price trend weakened.
8-KFiled 3 Nov 2026Biotech
Ultragenyx Pharmaceutical Inc.RARE
8-K · Items 2.01, 2.02, 2.05 — Acquisition or disposal of assets
Ultragenyx completed sale of PRV for $210M but announced 20% workforce reduction (~200 employees), ~$25M restructuring charges, termination of UX701 program, and wind-down of GTX-102 studies despite reaffirming 2027 profitability guidance.
The filings read less positively.
The gap closed as the filings read less positively.
8-KFiled 3 Nov 2026All industries
Fortune Brands Innovations, Inc.FBIN
8-K · Item 2.02 — Results of operations
Q3 2026 sales declined 3.1% YoY to $1.1B. GAAP EPS fell 28.8% to $0.42 due to $0.47 asset impairment. Company reduced full-year EPS guidance to $3.20–$3.30 from $3.37 midpoint, citing execution challenges, market softening, and portfolio divestitures (Fiberon, China exit, EMEA rationalization) expected to generate $50–$55M annualized operating losses.
No notable change in AIR's read.
10-QFiled 3 Nov 2026Industrials
Eastman Kodak CoKODK
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 3 Nov 2026Industrials
Eastman Kodak CoKODK
8-K · Item 2.02 — Results of operations
Q3 2026 revenue grew 3% YoY to $276M; gross profit up 7% to $73M; net income increased 62% to $21M. Advanced Materials & Chemicals surged 21% revenue growth. Cash generation of $27M in Q3 demonstrates operational strength despite Print segment decline.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 3 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 revenue declined 4.5% YoY to $69.8M from $73.1M. GAAP EPS improved to $0.14 vs $0.09, but adjusted EPS of $0.39 met guidance high-end. Nine-month revenue down 9.6% YoY. Debt increased to $86.1M.
The gap narrowed — attention is catching up.
The price trend strengthened.
10-QFiled 3 Nov 2026All industries
Atlas Energy Solutions Inc.AESI
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 3 Nov 2026All industries
Xometry, Inc.XMTR
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
The gap narrowed — attention is catching up.
The price trend strengthened.
10-QFiled 3 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
Sun 22 Nov
CAPR · Capricor Therapeutics, Inc. · Regulatory date
As stated in the filing: “Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026 ●”
Announced by the company in 8-K on 10 Nov 2026
DYN · Dyne Therapeutics, Inc. · Regulatory date
As stated in the filing: “Capricor Therapeutics’ BLA for its cell therapy deramiocel is currently under FDA review with a PDUFA date of November 22, 2026.”
Announced by the company in 10-Q on 5 Nov 2026
SVRA · Savara Inc · Regulatory date
As stated in the filing: “The FDA determined that the Company’s responses to recent information requests by the Agency during its review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026.”
Announced by the company in 10-Q on 9 Nov 2026
Fri 27 Nov
BBIO · BridgeBio Pharma, Inc. · Regulatory date
As stated in the filing: “The first participant was dosed in ASCEND-ATTR, the Phase 3b/4 study to prospectively test disease reversal with Attruby - BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review.”
Announced by the company in 8-K on 29 Oct 2026
Mon 30 Nov
COGT · Cogent Biosciences, Inc. · Regulatory date
As stated in the filing: “Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026 •”
Announced by the company in 8-K on 5 Nov 2026
JBIO · Jade Biosciences, Inc. · Regulatory date
As stated in the filing: “The FDA has also accepted a Biologics License Application for accelerated approval of povetacicept in IgAN, with a Prescription Drug User Fee Act target action date of November 30, 2026.”
Announced by the company in 10-Q on 13 Nov 2026
Wed 2 Dec
ARE · Alexandria Real Estate Equities, Inc. · Investor day
As stated in the filing: “We expect to introduce 2027 guidance and related assumptions at our Investor Day on December 2, 2026, consistent with our historical practice.”
Announced by the company in 8-K on 27 Apr 2026
Thu 3 Dec
EXEL · Exelixis, Inc. · Regulatory date
As stated in the filing: “In February 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.”
Announced by the company in 10-Q on 29 Oct 2026
Tue 8 Dec
GPC · Genuine Parts Co · Investor day
As stated in the filing: “In addition, the Company announced that both Global Automotive and Global Industrial will host separate investor days on December 8, 2026 and December 9, 2026, respectively.”
Announced by the company in 8-K on 9 Sep 2026
LGND · Ligand Pharmaceuticals Inc · Investor day
As stated in the filing: “Ligand will provide an updated 5-year outlook during the Company’s Investor Day on December 8, 2026.”
Announced by the company in 8-K on 14 Jul 2026
Wed 9 Dec
GPC · Genuine Parts Co · Investor day
As stated in the filing: “Investor Days GPC and Motion will host separate investor days in New York City, with GPC’s Investor Day scheduled for December 8, 2026, and Motion’s Investor Day scheduled for December 9, 2026.”
Announced by the company in 8-K on 9 Sep 2026
Sat 12 Dec
ANAB · Anaptysbio, Inc · Regulatory date
As stated in the filing: “FDA target action date (PDUFA) of December 12, 2026, for Quimilza in generalized pustular psoriasis (GPP) GSK and Tesaro Litigation Update •”
Announced by the company in 8-K on 12 Nov 2026
Thu 17 Dec
CORT · Corcept Therapeutics Inc · Regulatory date
As stated in the filing: “Relacorilant for patients with Cushing’s syndrome – Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026 “The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.”
Announced by the company in 8-K on 3 Nov 2026
Mon 23 Nov
MATW · Matthews International Corp · All industries
Annual results due — last year filed 21 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 30%, net income turned to a loss
AIR's current read: News flow Balanced, Gap Low · 0
Tue 24 Nov
BLBD · Blue Bird Corp · Industrials
Annual results due — last year filed 24 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 30%, net income up 408%
AIR's current read: News flow Balanced, Gap Very high · 82
PFLT · PennantPark Floating Rate Capital Ltd. · All industries
Annual results due — last year filed 24 Nov 2025
AIR's current read: News flow Balanced, Gap Very high · 71
Wed 25 Nov
AMTM · Amentum Holdings, Inc. · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2025, against a year earlier): revenue up 66%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 4
ARMK · Aramark · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2025, against a year earlier): revenue up 6%, net income up 23%
AIR's current read: News flow Balanced, Gap Medium · 10
CASH · Pathward Financial, Inc. · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 3%, net income down 31%
AIR's current read: News flow Balanced, Gap Low · 0
CLSK · Cleanspark, Inc. · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2024, against a year earlier): revenue up 129%, net loss widened
AIR's current read: News flow Balanced, Gap Very high · 54
GAP · Gap Inc · All industries
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q3 2024, against a year earlier): revenue down 7%, net income down 23%
AIR's current read: News flow Balanced, Gap Low · 3
ROAD · Construction Partners, Inc. · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 28%, net income up 35%
AIR's current read: News flow Balanced, Gap Low · 7
SJM · J M SMUCKER Co · All industries
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 7%, net loss widened
AIR's current read: News flow Balanced, Gap Low · 7
SMG · Scotts Miracle-Gro Co · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 1%, net income down 25%
AIR's current read: News flow Balanced, Gap Medium · 12
SMTC · Semtech Corp · Semiconductors
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q1 2027, against a year earlier): revenue up 16%, net income up 37%
AIR's current read: News flow Balanced, Gap Low · 0
TFSL · TFS Financial CORP · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q1 2019, against a year earlier): net income up 4%
AIR's current read: News flow Balanced, Gap Medium · 23
Fri 27 Nov
ATKR · Atkore Inc. · Industrials
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 8%, net income down 98%
AIR's current read: News flow Balanced, Gap Low · 0
BJ · BJ's Wholesale Club Holdings, Inc. · All industries
Quarterly results due — last year filed 26 Nov 2025
Last quarter (Q2 2027, against a year earlier): revenue up 16%, net income up 15%
AIR's current read: News flow Balanced, Gap Medium · 18
CENT · Central Garden & Pet Co · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 8%, net income down 5%
AIR's current read: News flow Balanced, Gap Low · 1
CFFN · Capitol Federal Financial, Inc. · Banks
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2020, against a year earlier): net income down 15%
AIR's current read: News flow Balanced, Gap Medium · 10
JJSF · J&J Snack Foods Corp · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 6%, net income down 20%
AIR's current read: News flow Balanced, Gap Low · 0
PD · PagerDuty, Inc. · Software / SaaS
Quarterly results due — last year filed 26 Nov 2025
Last quarter (Q1 2027, against a year earlier): revenue up 1%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 0
SPH · Suburban Propane Partners Lp · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue unchanged, net loss widened
AIR's current read: News flow Balanced, Gap Medium · 21
UTI · Universal Technical Institute Inc · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 7%, net income down 79%
AIR's current read: News flow Balanced, Gap Very high · 57
Mon 30 Nov
SNEX · StoneX Group Inc. · All industries
Annual results due — last year filed 28 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 15%, net income up 102%
AIR's current read: News flow Balanced, Gap Very high · 52
Tue 1 Dec
ESE · Esco Technologies Inc · Industrials
Annual results due — last year filed 1 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 14%, net income up 26%
AIR's current read: News flow Balanced, Gap Very high · 97
Wed 2 Dec
ASAN · Asana, Inc. · Software / SaaS
Quarterly results due — last year filed 2 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 10%, net loss narrowed
AIR's current read: News flow Balanced, Gap Low · 0
UNFI · United Natural Foods Inc · All industries
Quarterly results due — last year filed 2 Dec 2025
AIR's current read: News flow Balanced, Gap Low · 0
VSTS · Vestis Corp · All industries
Annual results due — last year filed 2 Dec 2025
Last quarter (Q3 2025, against a year earlier): revenue down 4%, net income turned to a loss
AIR's current read: News flow Balanced, Gap Low · 1
Thu 3 Dec
BOX · Box Inc · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 9%, net income up 43%
AIR's current read: News flow Balanced, Gap Low · 1
CRWD · CrowdStrike Holdings, Inc. · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 26%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 5
HQY · Healthequity, Inc. · All industries
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 8%, net income up 10%
AIR's current read: News flow Balanced, Gap Low · 0
KSS · KOHLS Corp · All industries
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q3 2024, against a year earlier): revenue down 5%, net income down 39%
AIR's current read: News flow Balanced, Gap Medium · 11
MEI · Methode Electronics Inc · Industrials
Quarterly results due — last year filed 3 Dec 2025
AIR's current read: News flow Balanced, Gap Low · 0
NCNO · nCino, Inc. · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 11%, net income up 145%
AIR's current read: News flow Balanced, Gap Low · 5
THO · Thor Industries Inc · Industrials
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q4 2026, against a year earlier): revenue down 8%, net income down 68%
AIR's current read: News flow Balanced, Gap Low · 4
Fri 4 Dec
AGX · Argan Inc · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 62%, net income up 51%
AIR's current read: News flow Balanced, Gap Low · 9
AMBA · Ambarella Inc · Semiconductors
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 13%, net loss narrowed
AIR's current read: News flow Balanced, Gap Low · 7
BF-B · Brown Forman Corp · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue down 1%, net income up 4%
AIR's current read: News flow Balanced, Gap Low · 0
CXM · Sprinklr, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 1%, net income down 44%
AIR's current read: News flow Balanced, Gap Low · 9
DCI · DONALDSON Co INC · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q4 2026, against a year earlier): revenue up 8%, net income up 13%
AIR's current read: News flow Balanced, Gap Low · 9
FIVE · Five Below, Inc · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2024, against a year earlier): revenue up 14%, net income down 10%
AIR's current read: News flow Balanced, Gap High · 27
GWRE · Guidewire Software, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 27%, net income down 64%
AIR's current read: News flow Balanced, Gap High · 44
NTNX · Nutanix, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 10%, net income up 14%
AIR's current read: News flow Balanced, Gap Medium · 22
REX · REX AMERICAN RESOURCES Corp · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 6%, net income up 336%
AIR's current read: News flow Balanced, Gap Low · 0
SAIC · Science Applications International Corp · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
AIR's current read: News flow Balanced, Gap High · 39
SWBI · Smith & Wesson Brands, Inc. · Industrials
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 32%, net income turned positive
AIR's current read: News flow Balanced, Gap Very high · 87
TITN · Titan Machinery Inc. · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue down 9%, net loss widened
AIR's current read: News flow Balanced, Gap Low · 0
Expected dates come from each company's filing history. They are not forecasts, and companies move them.
Sign in to follow companies
Follow a company and its filings show up here.
Sign inResearch, not tips. Filings come from SEC EDGAR; AIR's read is recomputed every trading day. A price move is shown as a fact beside a filing, never as the reason it is listed.